<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002181'>Cerebral edema</z:hpo> is a leading cause of mortality in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this study was to assess a non-selective opioid receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, biphalin, in decreasing reducing <z:hpo ids='HP_0002181'>brain edema</z:hpo> formation using both in vitro and in vivo models of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>For the in situ model of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, hippocampal slices were exposed to oxygen <z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation (OGD) conditions and we observed that hippocampal water content was increased, compared to normoxia </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with the mu <z:chebi fb="4" ids="48705">agonist</z:chebi>, Tyr<z:chebi fb="2" ids="29949">-D-Ala</z:chebi>', N-CH, -Phe4, Glyol-Enkephalin (DAMGO), delta opioid <z:chebi fb="4" ids="48705">agonists</z:chebi>, D-pen(2),<z:chebi fb="0" ids="29996"> D-phe</z:chebi>(5) enkephalin (DPDPE), and kappa <z:chebi fb="4" ids="48705">agonist</z:chebi>, U50 488, <z:hpo ids='HP_0000001'>all</z:hpo> significantly decreased brain slice water gain </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, the non-selective <z:chebi fb="4" ids="48705">agonist</z:chebi>, biphalin, exhibited a statistically significant (P&lt;0.01) greater effect in decreasing water content in OGD-exposed hippocampal slices, compared with mu, delta, and kappa selective opioid <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, biphalin exhibited anti-edematous effects in a dose responsive manner </plain></SENT>
<SENT sid="6" pm="."><plain>The non-selective opioid <z:chebi fb="68" ids="48706">antagonist</z:chebi>, <z:chebi fb="1" ids="7459">naloxone</z:chebi>, returned the water content nearly back to original OGD values for <z:hpo ids='HP_0000001'>all</z:hpo> opioid <z:chebi fb="4" ids="48705">agonist</z:chebi> treatments, supporting that these effects were mediated by an opioid receptor pathway </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, biphalin significantly decreased <z:hpo ids='HP_0000969'>edema</z:hpo> (53%) and <z:mpath ids='MPATH_124'>infarct</z:mpath> (48%) ratios, and neuronal recovery from <z:hpo ids='HP_0001297'>stroke</z:hpo>, compared with the vehicle-treated groups in a 12h permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Biphalin also significantly decreased the cell volume increase in primary neuronal cells exposed to OGD condition </plain></SENT>
<SENT sid="9" pm="."><plain>These data suggest that opioid receptor activation may provide neuroprotection during <z:hpo ids='HP_0001297'>stroke</z:hpo> and further investigations are needed in the development of novel opioid <z:chebi fb="4" ids="48705">agonist</z:chebi> as efficacious treatments for <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
</text></document>